Homology modeling and molecular dynamics studies of Wilms' tumor gene 1 frameshift mutations in exon 7.
暂无分享,去创建一个
Bairong Shen | J. Cen | Hong-jie Shen | X. Qi | Zi X. Chen | Shuiyan Wu | Ruihua Chen | Jian Pan | Shaoyan Hu | Ying Wang | Ming-ying Zhang
[1] Julia Kuhn,et al. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Raimondi,et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2010, Blood.
[3] Guido Marcucci,et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.
[4] Claude Pouchan,et al. The VCI-P code: an iterative variation–perturbation scheme for efficient computations of anharmonic vibrational levels and IR intensities of polyatomic molecules , 2010 .
[5] P. Zielenkiewicz,et al. Why similar protein sequences encode similar three-dimensional structures? , 2010 .
[6] R. Arceci. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system , 2010 .
[7] S. Raimondi,et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2010, Blood.
[8] R. Pieters,et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. , 2009, Blood.
[9] L. Bullinger,et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. , 2009, Blood.
[10] S. Raimondi,et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2009, Blood.
[11] H. Dyson,et al. Structure of the Wilms tumor suppressor protein zinc finger domain bound to DNA. , 2007, Journal of molecular biology.
[12] M. Minden,et al. A tumor suppressor and oncogene: the WT1 story , 2007, Leukemia.
[13] S. Ariyaratana,et al. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis , 2007, Expert Reviews in Molecular Medicine.
[14] M. Minden,et al. A tumor suppressor and oncogene: the WT1 story , 2007, Leukemia.
[15] [Suggestion of diagnosis and treatment of acute myelocytic leukemia in childhood]. , 2006, Zhonghua er ke za zhi = Chinese journal of pediatrics.
[16] I. Touw,et al. Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation , 2005, Oncogene.
[17] K. Pritchard-Jones,et al. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. , 1998, Blood.
[18] U. Maurer,et al. Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. , 1997, Blood.
[19] Y. Sonoda,et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. , 1997, Blood.
[20] M. Little,et al. A clinical overview of WT1 gene mutations , 1997, Human mutation.
[21] T. Kyo,et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. , 1996, Blood.
[22] K. Pritchard-Jones,et al. Mutations in the Wilms' tumor gene WT1 in leukemias. , 1996, Blood.
[23] S M Hewitt,et al. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. , 1995, Cancer research.
[24] T. Akiyama,et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.